inclusion criteria: participants are eligible to be included in the study only if all of the following criteria apply: 1. voluntarily participate in the study and sign the informed consent form. 2. adults aged 18 years and older at time of consent, male or female. 3. able to and willing to comply with study procedure based on the assessment of the investigator. 4. participants who have completed the second dose of 2-dose regimen of inactive vaccination (bbibp-corv or coronavac) against sars-cov-2 in the past 3-6 months (note: participants who received mixed vaccination of bbibp-corv and coronavac will not be enrolled). 5. healthy participants or participants with pre-existing stable medical conditions (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease within 3 months before enrollment). 6. males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination; and a female participant of childbearing potential should have a negative pregnancy test at screening and on the day of vaccination (day 0). female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause).

inclusion criteria: participants are eligible to be included in the study only if all of the following criteria apply: 1. voluntarily participate in the study and sign the informed consent form. 2. adults aged 18 years and older at time of consent, male or female. 3. able to and willing to comply with study procedure based on the assessment of the investigator. 4. participants who have completed the second dose of 2-dose regimen of inactive vaccination (bbibp-corv or coronavac) against sars-cov-2 in the past 3-6 months (note: participants who received mixed vaccination of bbibp-corv and coronavac will not be enrolled). 5. healthy participants or participants with pre-existing stable medical conditions (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease within 3 months before enrollment). 6. males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination; and a female participant of childbearing potential should have a negative pregnancy test at screening and on the day of vaccination (day 0). female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause).

inclusion criteria: participants are eligible to be included in the study only if all of the following criteria apply: voluntarily participate in the study and sign the informed consent form. adults aged 18 years and older at time of consent, male or female. able to and willing to comply with study procedure based on the assessment of the investigator. participants who have completed the second dose of 2-dose regimen of inactive vaccination (bbibp-corv or coronavac) against sars-cov-2 in the past 3-6 months (note: participants who received mixed vaccination of bbibp-corv and coronavac will not be enrolled). healthy participants or participants with pre-existing stable medical conditions (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease within 3 months before enrollment). males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination; and a female participant of childbearing potential should have a negative pregnancy test at screening and on the day of vaccination (day 0). female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause).

inclusion criteria: participants are eligible to be included in the study only if all of the following criteria apply: voluntarily participate in the study and sign the informed consent form. adults aged 18 years and older at time of consent, male or female. able to and willing to comply with study procedure based on the assessment of the investigator. participants who have completed the second dose of 2-dose regimen of inactive vaccination (bbibp-corv or coronavac) against sars-cov-2 in the past 3-6 months (note: participants who received mixed vaccination of bbibp-corv and coronavac will not be enrolled). healthy participants or participants with pre-existing stable medical conditions (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease within 3 months before enrollment). males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination; and a female participant of childbearing potential should have a negative pregnancy test at screening and on the day of vaccination (day 0). female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause).

inclusion criteria: participants are eligible to be included in the study only if all of the following criteria apply: 1. voluntarily participate in the study and sign the informed consent form. 2. adults aged 18 years and older at time of consent, male or female. 3. able to and willing to comply with study procedure based on the assessment of the investigator. 4. participants who have completed the second dose of 2-dose regimen of inactive vaccination (bbibp-corv or coronavac) against sars-cov-2 in the past 3-6 months (note: participants who received mixed vaccination of bbibp-corv and coronavac will not be enrolled). 5. healthy participants or participants with pre-existing stable medical conditions (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease within 3 months before enrollment). 6. males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination; and a female participant of childbearing potential should have a negative pregnancy test at screening and on the day of vaccination (day 0). female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause).

inclusion criteria: participants are eligible to be included in the study only if all of the following criteria apply: 1. voluntarily participate in the study and sign the informed consent form. 2. adults aged 18 years and older at time of consent, male or female. 3. able to and willing to comply with study procedure based on the assessment of the investigator. 4. participants who have completed the second dose of 2-dose regimen of inactive vaccination (bbibp-corv or coronavac) against sars-cov-2 in the past 3-6 months (note: participants who received mixed vaccination of bbibp-corv and coronavac will not be enrolled). 5. healthy participants or participants with pre-existing stable medical conditions (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease within 3 months before enrollment). 6. males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination; and a female participant of childbearing potential should have a negative pregnancy test at screening and on the day of vaccination (day 0). female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause).